Biotech mergers and acquisitions are gaining momentum as Big Pharma seeks to offset upcoming patent losses. Among potential targets, Legend Biotech stands out for its revenue-generating CAR-T therapy Carvykti, co-developed with Johnson & Johnson, showing strong sales growth and nearing profitability. Its share price is undervalued, making it an attractive acquisition candidate with minimal integration challenges. Revolution Medicines and Structure Therapeutics also present opportunities but face higher prices or clinical risks. Legend Biotech is the most actionable target as biotech dealmaking accelerates.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
